Hemodialysis vascular access dysfunction: From pathophysiology to novel therapies

Blood Purification

Volumn 21, Issue 1, 2003, Pages 99-110

  Roy Chaudhury, Prabir ^a,b   Kelly, Burnett S ^a   Zhang, Jianhua ^a   Narayana, Ashwath ^a   Desai, Pankaj ^a   Melhem, Murad ^a   Duncan, Heather ^a   Heffelfinger, Sue C ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Local therapy; Pig model; Smooth muscle cell proliferation; Venous neointimal hyperplasia; Venous stenosis

Indexed keywords

ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIOGLITAZONE; POLITEF; RAPAMYCIN; ROSIGLITAZONE; VERAPAMIL;

ADVENTITIA; ARTERY INTIMA PROLIFERATION; BLOOD VESSEL WALL; CLINICAL TRIAL; CONFERENCE PAPER; ELECTRON THERAPY; GAMMA IRRADIATION; GENE THERAPY; GRAFT FAILURE; HEMODIALYSIS VASCULAR ACCESS DYSFUNCTION; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; INTIMA; MATERIAL COATING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEM CELL; STENT; VASCULAR ACCESS; VEIN DISEASE; VEIN OCCLUSION; VENOUS NEOINTIMAL HYPERPLASIA;

ANIMALS; CATHETERIZATION; CATHETERS, INDWELLING; CONSTRICTION, PATHOLOGIC; HUMANS; HYPERPLASIA; MUSCLE, SMOOTH, VASCULAR; RENAL DIALYSIS;

EID: 0037256371     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067863     Document Type: Conference Paper

References (113)

1. USRDS: United States Renal Data System Annual Report. Minneapolis, United States Renal Data System, 2000.
2. Feldman HI Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996;7:523-535.
3. Schwab SJ, Harrington JT, Singh A, Roher R, Shohaib SA, Perrone RD, et al: Vascular access for hemodialysis. Kidney Int 1999;55:2078-2090.
4. Beathard GA: The treatment of vascular access dysfunction: A nephrologist's view and experience. Adv Ren Replace Ther 1994;1:131-147.
5. Himmelfarb J, Saad T: Hemodialysis vascular access: Emerging concepts. Curr Opin Nephrol Hypertens 1996;5:485-491.
6. Blankestijn PJ, Bosman PJ, Boereboom FT: Haemodialysis access without thrombosis: Is it possible? Nephrol Dial Transplant 1996;11: 2394-2397.
7. Chen C, Ku DN, Kikeri D, Lumsden AB: Tenascin: A potential role in human arteriovenous PTFE graft failure. J Surg Res 1996;60:409-416.
8. Rekhter M, Nicholls S, Ferguson M, Gordon D: Cell proliferation in human arteriovenous fistulas used for hemodialysis. Arterioscler Thromb 1993;13:609-617.
9. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC: Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989;80:1726-1736.
10. Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, Heffelfinger SC: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001;59:2325-2334.
11. Weiss MF, Scivittaro V, Anderson JM: Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis 2001;37:970-980.
12. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 2000;102:1697-1702.
13. Abbott WM: Aortofemoral bypass for atherosclerotic aortoiliac disease occlusive disease; in Ernst CB (ed): Current Therapy in Vascular Surgery. St Louis, Mosby Year Book, 1995, p 355.
14. Dalman RL: Infrainguinal revascularization procedures; in Porter JM (ed): Basic Data Underlying Clinical Decision-Making in Vascular Surgery. St Louis, Quality Medical Publishing, 1994, p 141.
15. Beathard GA: Mechanical versus pharmaco-mechanical thrombolysis for the treatment of thrombosed dialysis access grafts. Kidney Int 1994;45:1401-1406.
16. Beathard GA: Percutaneous angioplasty for the treatment of venous stenosis: A nephrologist's view. Semin Dial 1995;8:166-170.
17. Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW, Picus D: Dialysis access grafts: Anatomic location of venous stenosis and results of angioplasty (published erratum appears in Radiology 1995;196:582). Radiology 1995;195:135-139.
18. Turmel-Rodrigues L, Pengloan J, Blanchier D, Abaza M, Birmele B, Haillot O, et al: Insufficient dialysis shunts: Improved long-term patency rates with close hemodynamic monitoring, repeated percutaneous balloon angioplasty, and stent placement. Radiology 1993;187:273-278.
19. Motwani JG, Topol EJ: Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition and prevention. Circulation 1998;97:916-931.
20. Albers FJ: Causes of hemodialysis access failure. Adv Ren Replace Ther 1994;1:107-118.
21. Gnasso A, Irace C, Carallo C, De Franceschi MS, Motti C, Mattioli PL, et al: In vivo association between low wall shear stress and plaque in subjects with asymmetrical carotid atherosclerosis. Stroke 1997;28:993-998.
22. Ku DN, Giddens DP, Zarins CK, Glagov S: Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis 1985;5:293-302.
23. Meyerson SL, Skelly CL, Curi MA, Shakur UM, Vosicky JE, Glagov S, Schwartz LB, Christen T, Gabbiani G: The effects of extremely low shear stress on cellular proliferation and neointimal thickening in the failing bypass graft. J Vasc Surg 2001;34:90-97.
24. Mattsson EJ, Kohler TR, Vergel SM, Clowes AW: Increased blood flow induces regression of intimal hyperplasia. Arterioscler Thromb Vasc Biol 1997;17:2245-2249.
25. Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Ortiz M, Tagle R, Gonzalez F, Quiroga T, Caceres MS, Leighton F, Pereira J: Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001;60:1844-1850.
26. Morris ST, McMurray JJ, Spiers A, Jardine AG: Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 2001;60:1077-1082.
27. Danenberg HD, Fishbein I, Gao J, Monkkonen J, Reich R, Gati I, Moerman E, Golomb G: Macrophage depletion by clodronate containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002;106:599-605.
28. Welt FG, Edelman ER, Simon DI, Rogers C: Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon injured arteries. Arterioscler Thromb Vasc Biol 2000;20:2553-2558.
29. Tsui LV, Camrud A, Mondesire J, Carlson P, Zayek N, Camrud L, et al: p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion. Circ Res 2001;89:323-328.
30. McArthur JG, Qian H, Citron D, Banik GG, Lamphere L, Gyuris J, Tsui L, George SE: p27-p16 chimera: A superior anti-proliferative for the prevention of neointimal hyperplasia. Mol Ther 2001;3:8-13.
31. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, et al: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518-522.
32. Ohashi N, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, et al: Role of p38 mitogen-activated protein kinase in neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 2000;20:2521-2526.
33. Sirois MG, Simons M, Edelman ER: Antisense oligonucleotide inhibition of PDGFR-β receptor subunit expression directs suppression of intimal thickening. Circulation 1997;95:669-676.
34. Lindner V, Reidy MA: Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739-3743.
35. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK: Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 2000;102:1697-1702.
36. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF, Nishida K, Inoue S, Katoh M, Ichiki T, Takeshita A: Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 2002;90:1167-1172.
37. Usui M, Egashira K, Ohtani K, Kataoka C, Ishibashi M, Hiasa KI, Katoh M, Zhao Q, Kitamoto S, Takeshita A: Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J 2002(Sept 5).
38. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, Weber C: Deposition of platelet RANTES triggering monocyte recruitment requires P selectin and is involved in neointima formation after arterial injury. Circulation 2002;106:1523-1529.
39. Fukada J, Schena S, Tack I, Ruiz P, Kurimoto Y, Pang M, et al: Nitric oxide donor FK409 attenuates the development of neointimal hyperplasia in a rat aortic allograft model. Transplant Proc 2001;33(1-2):536-537.
40. McKenna CJ, Burke SE, Opgenorth TJ, Padley RJ, Camrud LJ, Camrud AR, et al: Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation 1998;97:2551-2556.
41. Zou Y, Hu Y, Mayr M, Dietrich H, Wick G, Xu Q: Reduced neointima hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-deficient mice. Circ Res 2000;86:434-440.
42. Wang K, Zhou Z, Zhou X, Tarakji K, Topol EJ, Lincoff AM: Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. J Am Coll Cardiol 2001;38:577-582.
43. Isoda K, Nishikawa K, Kamezawa Y, Yoshida M, Kusuhara M, Moroi M, Tada N, Ohsuzu F: Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res 2002;91:77-82.
44. Zhu B, Kuhel DG, Witte DP, Hui D: Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice. Am J Pathol 2000;157:1839-1848.
45. Hu Y, Baker AH, Zou Y, Newby AC, Xu Q: Local gene transfer of tissue inhibitor of metalloproteinase-2 influences vein-graft remodeling in a mouse model. Arterioscler Thromb Vasc Biol 2001;21:1275-1280.
46. Hayashi K, Nakamura S, Morishita R, Moriguchi A, Aoki M, Matsumoto K, Nakamura T, Kaneda Y, Sakai N, Ogihara T: In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 2000;7:1664-1671.
47. Humphries S, Bauters C, Meirhaeghe A, Luong L, Bertrand M, Amouyel P: The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J 2002;23:692-694.
48. Isbir CS, Akgun S, Yilmaz H, Civelek A, Ak K, Tekeli A, Agachan B, Cobanoglu A: Is there a role of angiotensin-converting enzyme gene polymorphism in the failure of arteriovenous femoral shunts for hemodialysis. Ann Vasc Surg 2001;15:443-446.
49. Libby P, Tanaka H: The molecular bases of restenosis. Prog Cardiovasc Dis 1997;40:97-106.
50. Nakamura Y, Zhao H, Yutani C, Imakita M, Ishibashi-Ueda H: Morphometric and histologic assessment of remodeling associated with restenosis after percutaneous transluminal coronary angioplasty. Cardiology 1998;90:115-121.
51. Keren G: Compensatory enlargement, remodeling, and restenosis. Adv Exp Med Biol 1997;430:187-196.
52. Schwartz RS, Topol EJ, Serruys PW, Sangiorgi G, Holmes DR Jr: Artery size, neointima and remodeling: Time for some standards. J Am Coll Cardiol 1998;32:2087-2094.
53. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A: Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996;94:1655-1664.
54. Roy-Chaudhury P, Miller M, Reaves A, Armstrong J, Duncan H, Munda R, Kelly B, Heffelfinger S: Adventitial fibroblasts contribute to venous neointimal hyperplasia in PTFE dialysis grafts (abstract). J Am Soc Nephrol 2001;12:287A.
55. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, et al: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002;8:403-409.
56. Sata M, Hirata W, Nagai R: Circulating recipient cells contribute to graft coronary arteriolosclerosis. J Cardiol 2002;39:48-49.
57. Bayes-Genis A, Campbell JH, Carlson PJ, Holmes DR Jr, Schwartz RS: Macrophages, myofibroblasts and neointimal hyperplasia after coronary artery injury and repair. Atherosclerosis 2002;163:89-98.
58. Kelly B Heffelfinger SC, Miller MA, Reaves A, Armstrong J, Whiting JF, Narayana A, Roy-Chaudhury P: Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. Kidney Int 2002;2:2272-2280.
59. Kohler TR, Kirkman TR: Dialysis access failure: A sheep model of rapid stenosis. J Vasc Surg 1999;30:744-751.
60. Chen C, Mattar SG, Hughes JD, Pierce GF, Cook JE, Ku DN, et al: Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft. Circulation 1996;94:1989-1995.
61. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, et al: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994;265:781-784.
62. Brieger D Topol E: Local drug delivery systems and prevention of restenosis. Cardiovasc Res 1997;35:405-413.
63. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, et al: Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195.
64. Fingerle J, Muller RM, Kuhn H, Pech M, Baumgartner HR: Mechanism of inhibition of neointimal formation by the angiotensin-converting enzyme inhibitor cilazapril. A study in balloon catheter-injured rat carotid arteries. Arterioscler Thromb Vasc Biol 1995;15:1945-1950.
65. Varty K, Allen KE, Jones L, Sayers RD, Bell PR, London NJ: Influence of losartan, an angiotensin receptor antagonist, on neointimal proliferation in cultured human saphenous vein. Br J Surg 1994;81:819-822.
66. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al: Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000;101:1311-1318.
67. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, et al: PPARγ ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 1999;33:798-806.
68. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, et al: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-1905.
69. Huang P, Hawthorne WJ, Peng A, Angeli GL, Medbury HJ, Fletcher JP: Calcium channel antagonist verapamil inhibits neointimal formation and enhances apoptosis in a vascular graft model. Am J Surg 2001;181:492-498.
70. Walter DH, Schachinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM: Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000;85:962-968.
71. Komukai M, Wajima YS, Tashiro J, Shinomiya M, Saito Y, Morisaki N: Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration. Scand J Clin Lab Invest 1999;59:159-166.
72. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, et al: Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137(suppl):101-109.
73. Dol F, Mares A, Herbert J: Simvastatin inhibits myointimal hyperplasia following carotid artery injury in cholesterol-fed rabbits. Blood Coagul Fibrinolysis 1996;7:772-778.
74. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R, Billingham ME, et al: Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995;59:655-661.
75. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, et al: Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164-2170.
76. Gradzki R, Roys E, Messana J: Association of the ACE-I use with prolonged PTFE hemodialysis access survival. J Am Soc Nephrol 2000;11:185A.
77. NIDDK. Dialysis Access Consortium, 2002.
78. Mayberg MR, Luo Z, London S, Gajdusek C, Rasey JS: Radiation inhibition of intimal hyperplasia after arterial injury. Radiat Res 1995;142:212-220.
79. Waksman R, Robinson KA, Crocker IR, Gravanis MB, Cipolla GD, King SB 3rd: Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine. A possible role for radiation therapy in restenosis prevention. Circulation 1995;91:1533-1539.
80. Wiedermann JG, Marboe C, Amols H, Schwartz A, Weinberger J: Intracoronary irradiation markedly reduces neointimal proliferation after balloon angioplasty in swine: Persistent benefit at 6-month follow-up. J Am Coll Cardiol 1995;25:1451-1456.
81. Haimovitz-Friedman A: Signaling in the radiation response of endothelial cells; in Rubin DB (ed): The Radiation Biology of the Vascular Endothelium. Boston, CRC Press, 1998, pp 101-127.
82. Rubin P, Williams JP, Riggs PN, Bartos S, Sarac T, Pomerantz R, et al: Cellular and molecular mechanisms of radiation inhibition of restenosis. I. Role of the macrophage and platelet-derived growth factor. Int J Radiat Oncol Biol Phys 1998;40:929-941.
83. Fareh J, Martel R, Kermani P, Leclerc G: Cellular effects of beta-particle delivery on vascular smooth muscle cells and endothelial cells: A dose-response study. Circulation 1999;99:1477-1484.
84. Waksman R: Local catheter-based intracoronary radiation therapy for restenosis. Am J Cardiol 1996;78:23-28.
85. Waksman R: Response to radiation therapy in animal restenosis models. Semin Interv Cardiol 1997;2:95-101.
86. Waksman R, Rodriguez JC, Robinson KA, Cipolla GD, Crocker IR, Scott NA, et al: Effect of intravascular irradiation on cell proliferation, apoptosis and vascular remodeling after balloon overstretch injury of porcine coronary arteries. Circulation 1997;96:1944-1952.
87. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, et al: Localized intra-coronary γ-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001;344:250-256.
88. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, et al: Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697-1703.
89. Raizner AE, Oesterle SN, Waksman R, Serruys PW, Colombo A, Lim YL, et al: Inhibition of restenosis with β-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 2000;102:951-958.
90. Sapirstein W, Zuckerman B, Dillard J: FDA approval of coronary-artery brachytherapy. N Engl J Med 2001;344:297-299.
91. Kelly B, Heffelfinger S, Miller MA, Reaves A, Armstrong J, Whiting JF, Roy-Chaudhury P: External beam radiation attenuates venous neointimal hyperplasia in arteriovenous PTFE grafts. Int J Radiat Oncol Biol Physics 2002 (in press).
92. Kim SJ, Rowley R, et al: Effect of radiation on arterial and venous smooth muscle cells in culture. J Am Soc Nephrol 2001;12:292A.
93. Parikh S, Nori D, Rogers D, Charytan C, Osian A, Al-Saloum M, Cavallo G: External beam radiation therapy to prevent postangioplasty dialysis access restenosis: A feasibility study. Cardiovasc Radiat Med 1999;1:36-41.
94. Cohen GS, Freeman H, Ringold MA, Putnam SG, Ball DS, Silverman C, Schulman G: External beam irradiation as an adjunctive treatment in failing dialysis shunts. J Vasc Interv Radiol 2000;11:321-326.
95. Qian HS, Channon K, Neplioueva V, Wang Q, Finer M, Tsui L, et al: Improved adenoviral vector for vascular gene therapy: Beneficial effects on vascular function and inflammation. Circ Res 2001;88:911-917.
96. Von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, et al: Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137-1141.
97. Shears LL 2nd, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovesdi I, et al: Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998;187:295-306.
98. Chang MW, Barr E, Lu MM, Barton K, Leiden JM: Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995;96:2260-2268.
99. Tsui LV, Camrud A, Mondesire J, Carlson P, Zayek N, Camrud L, Donahue B, Bauer S, Lin A, Frey D, Rivkin M, Subramanian A, Falotico R, Gyuris J, Schwartz R, McArthur JG: p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion. Circ Res 2001;89:323-328.
100. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, et al: Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 1999;354:1493-1498.
101. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR, et al: Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-2332.
102. Hong MK, Kornowski R, Bramwell O, Ragheb AO, Leon MB: Paclitaxel-coated Gianturco-Roubin (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis 2001;12:513-515.
103. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, et al: Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193.
104. Marx SO, Marks AR: Bench to bedside: The development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-855.
105. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R, RAVEL Study Group: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization stent. N Engl J Med 2002;346:1773-1780.
106. Cordis: Preliminary results of a large-scale US study support excellent results with Cordis Cypher™ sirolimus-eluting stent. Cordis, 2002.
107. Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, Smits PC, van der Giessen WJ, van den Brand M, de Feyter P, Popma JJ: Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: Long-term (up to 2 years) clinical, angiographic and intravascular ultrasound follow-up. Circulation 2002;106:1610-1613.
108. Grube E: Safety and feasibility data on JOMED tacrolimus-coated stents and stent grafts. Atlanta, American College of Cardiology, 2002.
109. Hoffer EK, Sultan S, Herskowitz MM, Daniels ID, Sclafani SJ: Prospective randomized trial of a metallic intravascular stent in hemodialysis graft maintenance. J Vasc Interv Radiol 1997;8:965-973.
110. Beathard GA: Gianturco self-expanding stent in the treatment of stenosis in dialysis access grafts. Kidney Int 1993;43:872-877.
111. Turmel-Rodrigues LA, Blanchard D, Pengloan J, Sapoval M, Baudin S, Testou D, et al: Wallstents and Craggstents in hemodialysis grafts and fistulas: Results for selective indications. J Vasc Interv Radiol 1997;8:975-982.
112. LaMuraglia GM, Schiereck J, Heckenkamp J, Nigri G, Waterman P, Leszczynski D, Kossodo S: Photodynamic therapy induces apoptosis in intimal hyperplastic arteries. Am J Pathol 2000;157:867-875.
113. Fitzgerald PJ, Takagi A, Moore MP, Hayase M, Kolodgie FD, Corl D, Nassi M, Virmani R, Yock PG: Intravascular sonotherapy decreases neointimal hyperplasia after stent implantation in swine. Circulation 2001;103:1828-31.